📊 GDRX Key Takeaways
Is GoodRx Holdings, Inc. (GDRX) a Good Investment?
GoodRx demonstrates solid fundamental strength with exceptional free cash flow generation (20.6% FCF margin) and improved profitability (Net Income +85.7% YoY, EPS +125% YoY), supported by healthy balance sheet metrics and strong liquidity. However, top-line growth remains anemic at 0.6% YoY revenue growth, which constrains the overall rating and suggests the company is reaching maturity in its core markets.
GoodRx shows solid underlying financial quality through strong free cash flow generation, good liquidity, and a sharp rebound in net income and diluted EPS. However, revenue growth is nearly flat and interest coverage is only moderate, which limits the strength of the fundamental outlook despite improved profitability.
Why Buy GoodRx Holdings, Inc. Stock? GDRX Key Strengths
- Exceptional free cash flow generation at $164.4M with 20.6% FCF margin demonstrates cash-generative business model
- Strong profitability improvement with net income growing 85.7% YoY and diluted EPS up 125% YoY shows operational leverage
- Healthy liquidity position with 2.61x current and quick ratios, supported by $261.8M cash and manageable 0.80x debt-to-equity ratio
- Adequate interest coverage of 3.0x indicates debt service capacity despite $495.0M long-term debt
- Strong free cash flow generation with a 20.6% FCF margin
- Healthy balance sheet liquidity with current and quick ratios of 2.61x
- Net income and diluted EPS improved materially year over year
GDRX Stock Risks: GoodRx Holdings, Inc. Investment Risks
- Revenue growth near flat at 0.6% YoY indicates minimal top-line expansion and potential market saturation in core healthcare discount business
- Low profit margins (3.8% net margin, 11.0% operating margin) limit financial cushion and reinvestment capacity
- Material long-term debt of $495.0M represents 80% of equity, reducing financial flexibility for strategic investments or downturns
- Modest ROE of 4.9% and ROA of 2.2% suggest limited return generation relative to capital employed
- Revenue growth of 0.6% suggests limited top-line momentum
- Interest coverage of 3.0x leaves less room if operating performance weakens
- Net margin of 3.8% remains modest relative to the company's cash flow profile
Key Metrics to Watch
- Revenue growth trajectory - critical to confirm return to organic growth above 2-3% annually
- Operating margin expansion - potential upside if company can leverage scale to improve 11.0% current level
- Free cash flow sustainability - maintain 15%+ FCF margins and debt reduction trajectory
- Debt reduction pace - monitor progress toward deleveraging from current 0.80x debt-to-equity ratio
- Revenue growth acceleration
- Interest coverage and debt reduction progress
GoodRx Holdings, Inc. (GDRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 20.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.61x current ratio provides a solid financial cushion.
GDRX Profit Margin, ROE & Profitability Analysis
GDRX vs Technology Sector: How GoodRx Holdings, Inc. Compares
How GoodRx Holdings, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GoodRx Holdings, Inc. Stock Overvalued? GDRX Valuation Analysis 2026
Based on fundamental analysis, GoodRx Holdings, Inc. shows some fundamental concerns relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GoodRx Holdings, Inc. Balance Sheet: GDRX Debt, Cash & Liquidity
GDRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GoodRx Holdings, Inc.'s revenue has shown modest growth of 7% over the 5-year period. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
GDRX Revenue Growth, EPS Growth & YoY Performance
GDRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $195.3M | -$1.0M | $0.00 |
| Q2 2025 | $200.6M | -$1.0M | $0.01 |
| Q1 2025 | $197.9M | -$1.0M | $0.00 |
| Q3 2024 | $180.0M | -$1.0M | $0.01 |
| Q2 2024 | $189.7M | -$1.0M | $0.01 |
| Q1 2024 | $184.0M | -$1.0M | $0.00 |
| Q3 2023 | $180.0M | -$1.4M | $0.04 |
| Q2 2023 | $189.7M | -$1.4M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GoodRx Holdings, Inc. Dividends, Buybacks & Capital Allocation
GDRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GoodRx Holdings, Inc. (CIK: 0001809519)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GDRX
What is the AI rating for GDRX?
GoodRx Holdings, Inc. (GDRX) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (HOLD) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GDRX's key strengths?
Claude: Exceptional free cash flow generation at $164.4M with 20.6% FCF margin demonstrates cash-generative business model. Strong profitability improvement with net income growing 85.7% YoY and diluted EPS up 125% YoY shows operational leverage. ChatGPT: Strong free cash flow generation with a 20.6% FCF margin. Healthy balance sheet liquidity with current and quick ratios of 2.61x.
What are the risks of investing in GDRX?
Claude: Revenue growth near flat at 0.6% YoY indicates minimal top-line expansion and potential market saturation in core healthcare discount business. Low profit margins (3.8% net margin, 11.0% operating margin) limit financial cushion and reinvestment capacity. ChatGPT: Revenue growth of 0.6% suggests limited top-line momentum. Interest coverage of 3.0x leaves less room if operating performance weakens.
What is GDRX's revenue and growth?
GoodRx Holdings, Inc. reported revenue of $796.9M.
Does GDRX pay dividends?
GoodRx Holdings, Inc. pays dividends, with $1,346.4M distributed to shareholders in the trailing twelve months.
Where can I find GDRX SEC filings?
Official SEC filings for GoodRx Holdings, Inc. (CIK: 0001809519) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GDRX's EPS?
GoodRx Holdings, Inc. has a diluted EPS of $0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GDRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GoodRx Holdings, Inc. has a BUY rating with 76% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is GDRX stock overvalued or undervalued?
Valuation metrics for GDRX: ROE of 4.9% (sector avg: 22%), net margin of 3.8% (sector avg: 18%). Compare these metrics with sector averages to assess valuation.
Should I buy GDRX stock in 2026?
Our dual AI analysis gives GoodRx Holdings, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GDRX's free cash flow?
GoodRx Holdings, Inc.'s operating cash flow is $167.9M, with capital expenditures of $3.5M. FCF margin is 20.6%.
How does GDRX compare to other Technology stocks?
Vs Technology sector averages: Net margin 3.8% (avg: 18%), ROE 4.9% (avg: 22%), current ratio 2.61 (avg: 2.5).